CytoSorbents

#Critical Care #Cardiac Surgery #Blood Purification

Publicly traded company (NASDAQ:CTSO) in Princeton, NJ. Develops CytoSorb, an extracorporeal blood purification cartridge. FDA Breakthrough Device Designation for removal of ticagrelor and DOACs in cardiac surgery.

Company Info

Sector:Devices - Miscellaneous

Headquarters:Princeton, NJ, USA

Founded:1998

Website:cytosorbents.com/

Upcoming Milestones & Key Dates

2026-09-15

Regulatory

FDA Pre-submission meeting for DrugSorb-ATR

Clinical Development Pipeline

CytoSorb

Target: Blood purification

Removal of ticagrelor and DOACs in cardiac surgery

Preclinical

Phase 1

Phase 2

Phase 3

Approved

DrugSorb-ATR

Target: Blood purification

Removal of ticagrelor and DOACs

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Dr. Phillip Chan

CEO

Kathleen Bloch

CFO

Dr. Vincent Capponi

COO

Careers & Job Openings

See all open roles

Various

Princeton, NJ

Apply Now →